◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocksPFE › Gross Profit

Pfizer Inc (PFE) Gross Profit 2006–TTM

DATA UPDATED 2026-07-12

Pfizer Inc annual gross profit for fiscal TTM was $43.9 billion, a decrease of 0.2% from $44.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

PFE Annual Gross Profit

Gross Profit (annual)TTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Gross Profit$43.9B$44.0B$41.8B$30.3B$62.1B$46.9B$29.9B$28.5B$37.6B$36.8B$36.9B$35.7B$36.3B$37.6B$40.0B$43.9B$46.3B$38.4B$38.3B$36.7B$37.9B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PFE Quarterly Gross Profit

Gross Profit (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Gross Profit$9.7B$12.3B$12.5B$9.4B$9.8B$13.0B$10.8B$8.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More PFE metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All PFE financial statements → Interactive PFE charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.